Clinical Trial Update: Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating erlotinib and momelotinib for EGFR-mutated, EGFR TKI-naive metastatic non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Momelotinib (momelotinib)
• Tarceva (erlotinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: EGFR Mutated EGFR TKI Naive Metastatic NSCLC | Phase 1 | Status: TERMINATED